未名醫藥(002581.SZ):未名集團所持公司股份被輪候凍結約1.3853億股
格隆匯10月21日丨未名醫藥(002581.SZ)公佈,公司在中國證券登記結算有限責任公司深圳分公司查詢證實,公司控股股東北京北大未名生物工程集團有限公司(“未名集團”)所持有的公司股份被法院輪候凍結,輪候凍結138,531,020股。
經詢問,截至公吿披露日,未名集團尚未收到此次股份輪候凍結相關的法律文書、通知文件,暫不能確認上述股份被輪候凍結的具體原因。公司無法獲悉未名集團股份被輪候凍結的具體原因和詳細內容。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.